Status
Conditions
Treatments
About
The purpose of this study is to test the hypothesis that the addition of home-based hospice and palliative care (HBHPC) will provide a reduction in health care utilization, improve quality of life, and facilitate goal-concordant care that is superior to inpatient and clinic pediatric palliative care (PPC) alone.
Full description
Identify difference in outcomes between those that receive home-based hospice and palliative care (HBHPC) in conjunction with inpatient and clinic based palliative care compared to those who receive only inpatient and clinic based palliative care. Outcomes analyzed will include hospital utilization including ICU days, inpatient hospital days, ED visits, quality of life as defined by the individual and/or primary caregivers through PEDSQL2 Family Impact Module survey, and delivery of goal concordant care by individual and family.
This is a prospective, multi-site, quasi-experimental design using an untreated comparison group with dependent pretest and posttest samples. This trial is being carried out at five sites including: Nationwide Children's Hospital (lead/primary site; Columbus, OH), Akron Children's Hospital (Akron, OH), Texas Children's Hospital (Houston, TX), Nemours Hospital (Wilmington, DE), and Medical University of South Carolina (Charleston, SC). The experimental group consists of all participants from sites with high-access HBHPC programs and the untreated comparison group consisting of all participants from sites with low-volume HBHPC. Protocols, consistent across all sites, are being submitted independently to the site's respective IRB for review and approval. The intent is to pool deidentified data for aggregate analysis by NCH.
This non-random design is selected because it is neither logistically feasible nor clinically ethical to conduct a randomized trial in which some participants would be allocated to not receive the intervention (HBHPC). Use of a pretest and comparison group minimizes threats to validity; the lack of randomization allows the potential for selection bias. However, we anticipate that given the diagnostic and clinical diversity of the sample, and the dearth of HBHPC access for pediatric patients, that clinical acuity will naturally be matched between both cohorts.
At or within the first few weeks of completing informed consent, participants will complete the study surveys. Study staff will recontact participants every three months to recomplete the surveys using a REDCap link, or paper surveys sent and returned via participant's preferred method (and entered into REDCap by study staff).
At or within the first few weeks of completing informed consent, participants will complete the study surveys (PEDSQL2 Family Impact Module Quality of Life survey and Goal Concordant Care survey). Study staff will recontact participants in three month intervals for a two year period or patient death if death occurs within study period to recomplete the surveys using a REDCap link, or paper surveys sent and returned, or completed by phone call via participant's preferred method (and entered into REDCap by study staff). NCH staff will create the REDCap, and give the template to each site for consistency purposes. Study staff will collect clinical and demographic information from the electronic medical record. Study staff will securely transfer site REDCap clinical, demographic, and survey data to the primary site (NCH) for analysis. Each site PI or CRC will complete their own patient follow up for survey completion. Any identifiable information will be stored separately from the study data and only PIs and coordinators at each site will have access to their own access to PHI. Aggregate data will be reviewed as a whole.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
250 participants in 2 patient groups
Loading...
Central trial contact
Catherine Roth, MPH
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal